For the clinical development of new drugs, it is particularly important to develop an overall clinical strategy, combining un-met medical needs and known treatments prior to First-in-Human.
Integrated Services & Its Advantages
Ability to quickly provide overall clinical development strategies for Class I-III drugs in various categories, including first-in-class, me-too, modified new drugs.
Efficient support of communications with CDE for better results, such as writing/reviewing conference materials and meeting minutes, live presentations and information exchanges.
Rapid delivery of Phase I-III clinical trial protocols, within the overall development strategy framework.
CR Medicon specially established a clinical development strategy team for new drugs. Supported by our registration experts, statistical experts and medical experts combined, we provide key strategic advice for clients' new drug development.